Athens Medical Centre (STU:ACS) Research & Development: €0.0 Mil (TTM As of Dec. 2025)


STU:ACS Athens Medical Centre SA STU:ACS
60 GF Score
Price €1.59
GF Value €1.93
! 8 Warning Signs
View Full Analysis

What is Athens Medical Centre Research & Development?

Athens Medical Centre STU:ACS 60 Research & Development is €0.0 Mil as of Dec. 2025. GuruFocus rates STU:ACS with a GF Score™ of 60/100 and a GF Value™ of €1.93. The stock has 8 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Athens Medical Centre's Research & Development for the six months ended in Dec. 2025 was €0.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was €0.0 Mil.

Athens Medical Centre  (STU:ACS) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Athens Medical Centre Research & Development Related Terms

Athens Medical Centre Research & Development Historical Data

* Premium members only.

The historical data trend for Athens Medical Centre's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Athens Medical Centre Research & Development Chart

Athens Medical Centre Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Athens Medical Centre Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
STU:ACS
60GF Score
Athens Medical Centre SA STU:ACS
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Athens Medical Centre Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €0.0 Mil mean?
Athens Medical Centre (STU:ACS) has a Research & Development of €0.0 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Athens Medical Centre and its competitors.
Is Athens Medical Centre's Research & Development too high?
Athens Medical Centre's current Research & Development is €0.0 Mil. Overall, Athens Medical Centre has a GF Score™ of 60/100, reflecting its overall financial health beyond just this single metric.
How does Athens Medical Centre's Research & Development compare to HCA and THC?
Athens Medical Centre's Research & Development of €0.0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Athens Medical Centre and its competitors. Athens Medical Centre's current Research & Development is €0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Athens Medical Centre stock overvalued right now?
Athens Medical Centre (STU:ACS) has a current Research & Development of €0.0 Mil. The stock's GF Value™ is €1.93, compared to a current price of €1.59 — trading 17.9% below its estimated fair value. The current Research & Development is €0.0 Mil. Athens Medical Centre's overall GF Score™ is 60/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Athens Medical Centre (STU:ACS), the current Research & Development is €0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Athens Medical Centre (STU:ACS) Overvalued in 2026?

Based on GuruFocus' analysis, Athens Medical Centre stock appears to be undervalued. The current stock price of €1.59 is trading 17.9% below its estimated GF Value™ of €1.93.

Key valuation signals for STU:ACS:

  • Research & Development: €0.0 Mil
  • GF Value™: €1.93 vs. price of €1.59 (17.9% below fair value)
  • GF Score™: 60/100 with 8 warning signs

No single metric tells the full story. See the STU:ACS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Athens Medical Centre Business Description

Other Exchanges IATR:GreeceACS:Germany
Address 5-7 Distomou Street Maroussi, Athens, GRC, 15125
Athens Medical Centre SA engages in the provision of healthcare services. It includes medical research and methods of treatment, training, and selection of executives and staff on behalf of the hospitals and importation of medical tools, instruments, machinery, and automated devices for the hospitals. Its offering includes medical services in such specializations as pathology, cardiology, general surgery, plastic and vascular surgery, orthopedic, physiotherapy, ophthalmology, urology, neurosurgery, thoracic, pediatric, dermatology, endocrinology and stomatology. The company operates in Domestic healthcare service, Healthcare service provided abroad (Romania) and Sale of medical tools & sanitary/health equipment segment.
60GF Score

Get the complete analysis for STU:ACS

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.59
Price
€1.93
GF Value